Payment overview · 2025
General Payments
$140,000.39
135 reported records · 10 companies
Healthcare provider profile · identity verified
Amin A. Yehya, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Advanced Heart Failure and Transplant Cardiology · NORFOLK, VA · NPI 1376720946
Verified facts
What the public records show
CMS Open Payments records show Amin A. Yehya, MD received $140,000.39 in general payments during 2025 across 135 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Furoscix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 428 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Verquvo by this doctor in 2024.
SCPHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FUROSCIX as an associated drug or biological on 18968 records involving 9678 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Furoscix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52,228.89 | 37.3% | 44 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $27,249.40 | 19.5% | 20 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $21,633.91 | 15.4% | 6 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $11,222.17 | 8.0% | 31 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $10,598.34 | 7.6% | 12 | 2025 |
| Nuwellis, Inc. | Unresolved — no canonical attribution shown | $9,512.33 | 6.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $6,419.06 | 4.6% | 12 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $896.00 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $145.47 | 0.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.82 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,326.00 | 17 |
| Consulting Fee | $46,175.00 | 9 |
| Honoraria | $25,600.00 | 6 |
| Travel and Lodging | $10,874.38 | 39 |
| Food and Beverage | $4,632.68 | 62 |
| Education | $392.33 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46,444.89 | 42 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $27,249.40 | 20 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $21,633.91 | 6 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $11,222.17 | 31 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $10,598.34 | 12 | 2025 |
Source payment records
|
|||||
| Aquadex Smartflow Console Normalized: aquadex smartflow console |
Device | Nuwellis, Inc. | $9,512.33 | 5 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $6,419.06 | 12 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $114.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $94.82 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $11.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FUROSCIX furoscix |
2025 | Furoscix | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
428 | 100 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 28 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| SCPHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | FUROSCIX open payments reported associated product |
CMS Open Payments — General Payments 18968 supporting records · 9678 recipient NPIs · example record 1228171755 |
Furoscix · 2024 Exact normalized brand match · 1 Part D row |
25 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Entresto | Sacubitril/Valsartan | 493 | 102 |
| Farxiga | Dapagliflozin Propanediol | 428 | 100 |
| Spironolactone | Spironolactone | 426 | 120 |
| Furosemide | Furosemide | 361 | 106 |
| Carvedilol | Carvedilol | 332 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 159 | 50 |
| Bumetanide | Bumetanide | 134 | 45 |
| Jardiance | Empagliflozin | 120 | 28 |
| Losartan Potassium | Losartan Potassium | 98 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 31 |
| Verquvo | Vericiguat | 81 | 15 |
| Warfarin Sodium | Warfarin Sodium | 71 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 17 |
| Potassium Chloride | Potassium Chloride | 64 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 14 |
| Eliquis | Apixaban | 53 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 17 |
| Torsemide | Torsemide | 47 | 13 |
| Eplerenone | Eplerenone | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Furoscix | Furosemide | 25 | 18 |
| Camzyos | Mavacamten | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 17 |
| Tacrolimus | Tacrolimus | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lisinopril | Lisinopril | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140,000.39 · 135 records | Bayer Healthcare Pharmaceuticals Inc. | Aquadex Smartflow Console, Assure WCD, Attruby, Barostim Neo System, CARDIOMEMS, FUROSCIX, Kerendia, LOKELMA, PERCLOSE PROSTYLE, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Furoscix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error